Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024 4:01 PM EDT- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies
- Alpines lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 -
- Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway -
- Alpines protein engineering and immunotherapy expertise augments Vertexs toolbox and capabilities -
- Vertex to host investor call today, April 10, at 4:30 pm ET -
BOSTON &... More
